Valuation: Innoviva, Inc.

Market Cap 1.53B 1.33B 1.26B 1.14B 2.14B 146B 2.14B 15.01B 5.8B 74.49B 5.74B 5.61B 240B P/E 2026 *
9.82x
P/E 2027 * 9.07x
Enterprise Value 1.1B 954M 901M 818M 1.53B 105B 1.54B 10.76B 4.16B 53.42B 4.11B 4.02B 172B EV / Sales 2026 *
2.45x
EV / Sales 2027 * 1.83x
Free-Float
98.99%
Yield 2026 *
-
Yield 2027 * -
1 day+0.43%
1 week+2.32%
Current month+1.78%
1 month-1.58%
3 months-6.00%
6 months-4.30%
Current year+5.75%
1 week 20.5
Extreme 20.5
21.42
1 month 20.45
Extreme 20.45
21.51
Current year 19
Extreme 19
25.14
1 year 16.52
Extreme 16.52
25.14
3 years 12.22
Extreme 12.22
25.14
5 years 10.64
Extreme 10.64
25.14
10 years 7.58
Extreme 7.58
25.14
Manager TitleAgeSince
Chief Executive Officer 42 20/05/2020
Director of Finance/CFO 60 21/08/2023
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 75 12/02/2018
Director/Board Member 66 12/02/2018
Director/Board Member 42 19/05/2025
Date Insider Type Main position Quantity % Market Cap. Importance
20/8/26 Tax

Controller/Auditor

-1,127 0.0015%
20/8/26 Tax

Chief Executive Officer

-1,130 0.0015%
20/8/26 Tax

Chief Financial Officer

-558 0.0008%
Change 5-day change 1-year change 3-year change Capi.($)
+0.43%+2.32%+10.16%+69.39% 1.53B
+0.04%+3.34%+53.32%+100.52% 1,028B
-0.09%+1.66%+53.24%+66.45% 651B
-0.02%+2.66%+18.65%+71.97% 466B
-1.22%+3.66%+34.59%+38.81% 346B
-0.79%+2.73%+17.73%+25.11% 266B
+0.58%+6.76%+10.58%+17.75% 259B
+1.55%+2.20%+35.12%+45.91% 208B
+0.79%+1.84%-27.55%-56.48% 191B
-0.52%+4.45%+31.57%+98.11% 186B
Average +0.08%+3.16%+23.74%+47.75% 360.33B
Weighted average by Cap. -0.04%+3.09%+34.83%+61.60%

Financials

2026 *2027 *
Net sales 447M 389M 367M 334M 625M 42.8B 627M 4.39B 1.7B 21.78B 1.68B 1.64B 70.06B 489M 426M 402M 365M 684M 46.85B 686M 4.8B 1.86B 23.83B 1.84B 1.79B 76.67B
Net income 175M 153M 144M 131M 245M 16.8B 246M 1.72B 665M 8.54B 658M 643M 27.49B 183M 160M 151M 137M 257M 17.58B 257M 1.8B 696M 8.94B 689M 673M 28.77B
Net Debt -432M -376M -355M -323M -604M -41.41B -607M -4.24B -1.64B -21.07B -1.62B -1.59B -67.78B -631M -549M -519M -471M -883M -60.47B -886M -6.2B -2.4B -30.76B -2.37B -2.32B -98.97B
Logo Innoviva, Inc.
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. Its royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, it is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. Its products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO, is for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in a Phase III clinical trial.
Employees
159
Date Price Change Volume
18/09/26 USD 21.14 +0.43% 1,437,041
17/09/26 USD 21.05 -0.71% 1,251,905
16/09/26 USD 21.20 +1.73% 715,398
15/09/26 USD 20.84 -0.29% 1,102,033
14/09/26 USD 20.90 +1.16% 885,412
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
21.14USD
Average target price
35.00USD
Spread / Average Target
+65.56%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INVA Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!